FrancophonIA/ELRC3.0 huggingface dataset:
English: The active substance in Sprimeo, aliskiren, is a renin inhibitor.
Slovenian: Zdravilna učinkovina zdravila Sprimeo, aliskiren, spada med zaviralce renina.
English: Sprimeo may be taken alone or in combination with other medicines for hypertension, with the exception of ‘angiotensin converting enzyme (ACE) inhibitors' or ‘angiotensin receptor blockers' (ARBs) in patients with diabetes, or moderate or severe kidney impairment.
Slovenian: Zdravilo Sprimeo se lahko jemlje samostojno ali v kombinaciji z drugimi zdravili za zdravljenje hipertenzije z izjemo „zaviralcev angiotenzinske konvertaze (ACE)“ ali „zaviralcev angiotenzinskih receptorjev (ARB)“ pri bolnikih s sladkorno boleznijo oziroma zmerno ali hudo okvaro ledvic.
English: Sprimeo on its own was more effective than placebo and as effective as comparator treatments in reducing blood pressure.
Slovenian: Zdravilo Sprimeo kot samostojno zdravilo je bilo pri zdravljenju visokega krvnega tlaka učinkovitejše od placeba in enako učinkovito kot zdravljenje s primerljivimi zdravili.
English: Combination studies looked at Sprimeo used with an ACE inhibitor (ramipril), an ARB (valsartan), a beta-blocker (atenolol), a calcium-channel blocker (amlodipine) and a diuretic (hydrochlorothiazide).
Slovenian: V študijah kombinacij zdravil so zdravilo Sprimeo proučevali v kombinaciji z zaviralcem angiotenzinske konvertaze (ramiprilom), zaviralcem angiotenzinskih receptorjev (valsartanom), zaviralcem receptorjev beta (atenololom), zaviralcem kalcijevih kanalčkov (amlodipinom) in diuretikom (hidroklorotiazidom).
English: How has Sprimeo been studied?
Slovenian: Kako je bilo zdravilo Sprimeo raziskano?
English: How is Sprimeo used?
Slovenian: Kako se zdravilo Sprimeo uporablja?
English: The dose of Sprimeo may be increased to 300 mg once a day in patients whose blood pressure is not adequately controlled.
Slovenian: Pri bolnikih, katerih krvni tlak ni ustrezno uravnan, se lahko odmerek zdravila Sprimeo poveča na 300 mg enkrat na dan.
English: How does Sprimeo work?
Slovenian: Kako zdravilo Sprimeo deluje?
English: Sprimeo in combination with an ACE inhibitor or an ARB must not be used in patients with diabetes, or moderate or severe kidney impairment.
Slovenian: Zdravilo Sprimeo se v kombinaciji z zaviralcem angiotenzinske konvertaze ali zaviralcem angiotenzinskih receptorjev ne sme uporabljati pri bolnikih s sladkorno boleznijo oziroma zmerno ali hudo okvaro ledvic.
English: What is Sprimeo?
Slovenian: Kaj je zdravilo Sprimeo?
English: They are available in Austria, Belgium, Bulgaria, Czech Republic, Germany, Greece, Hungary, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovakia and Slovenia.
Slovenian: Na voljo so v Avstriji, Belgiji, Bolgariji, Češki republiki, Nemčiji, Grčiji, na Madžarskem, v Italiji, Latviji, Litvi, Luksemburgu, na Malti, Poljskem, Portugalskem, v Romuniji, na Slovaškem in v Sloveniji.
English: The review of bacterial lysate medicines was initiated on 28 June 2018 at the request of Italy, under Article 31 of Directive 2001/83/EC.
Slovenian: Pregled zdravil na osnovi bakterijskih lizatov se je začel 28. junija 2018 na zahtevo Italije v skladu s členom 31 Direktive 2001/83/ES.
English: The CHMP opinion was forwarded to the European Commission, which issued a final legally binding decision applicable in all EU Member States on 09 September 2019.
Slovenian: Mnenje odbora CHMP je bilo predloženo Evropski komisiji, ki je 9. septembra 2019 izdala končni pravno zavezujoči sklep, ki velja za vse države članice EU.
English: • If you have any questions or concerns about your medicine, discuss them with your doctor or pharmacist.
Slovenian: • Če imate kakršna koli vprašanja ali pomisleke glede svojega zdravila, se posvetujte z zdravnikom ali farmacevtom.
English: They are sold under several brand names including Broncho Munal, Broncho Vaxom, Buccalin, Immubron, Immucytal, Ismigen, Lantigen B, Luivac, Ommunal, Paspat, Pir-05, Polyvaccinum, Provax, Respivax and Ribomunyl.
Slovenian: Prodajajo se pod različnimi trgovskimi imeni, med drugim Broncho Munal, Broncho Vaxom, Buccalin, Immubron, Immucytal, Ismigen, Lantigen B, Luivac, Ommunal, Paspat, Pir-05, Polyvaccinum, Provax, Respivax in Ribomunyl.
English: Bacterial lysate medicines have been authorised via national procedures.
Slovenian: Zdravila na osnovi bakterijskih lizatov so bila odobrena po nacionalnih postopkih.
English: The CHMP therefore recommended that use of the medicines for prevention can continue, but the companies must provide further data on safety and effectiveness from new clinical studies by 2026.
Slovenian: Odbor CHMP je zato priporočil, da se lahko ta zdravila še dalje uporabljajo za preprečevanje, vendar morajo podjetja do leta 2026 zagotoviti dodatne podatke o varnosti in učinkovitosti teh zdravil na podlagi novih kliničnih študij.
English: These medicines are taken by mouth (as capsules, tablets, granules/powder for making up an oral mixture or drops), dissolved under the tongue (as tablets), inhaled through the nose (as a liquid) or given by injection into a muscle or under the skin.
Slovenian: Ta zdravila se jemljejo peroralno (v obliki kapsul, tablet, zrnc/praška za pripravo peroralne zmesi ali kapljic), se raztopijo pod jezikom (v obliki tablet), se inhalirajo skozi nos (v obliki tekočine) ali pa se injicirajo v mišico ali podkožje.
English: • If you have an infection and are taking a bacterial lysate medicine to treat it, or if you are taking one of these medicines to prevent pneumonia, contact your doctor or pharmacist for advice on alternatives.
Slovenian: • Če imate okužbo in jemljete katero koli zdravilo na osnovi bakterijskih lizatov za zdravljenje te okužbe ali če jemljete katero koli od teh zdravil za namene preprečevanja pljučnice, se z zdravnikom ali farmacevtom posvetujete o alternativnih možnostih zdravljenja.
English: Bacterial lysate medicines are made from bacterial cells that are broken down and are intended to stimulate the immune system to recognise and fight infections.
Slovenian: Zdravila na osnovi bakterijskih lizatov se izdelujejo s pomočjo razgrajenih bakterijskih celic, ki naj bi spodbudile imunski sistem k prepoznavanju okužb in obrambi pred njimi.
English: Although data are limited, the review found some evidence of effectiveness of these medicines in the prevention of recurrent respiratory tract infections and the safety profile is in line with what is expected for this type of product.
Slovenian: Čeprav so razpoložljivi podatki omejeni, je bilo pri pregledu ugotovljeno, da obstajajo dokazi o učinkovitosti teh zdravil pri preprečevanju ponavljajočih se okužb dihal in da je njihov varnostni profil v skladu s pričakovanji za to vrsto zdravil.
English: In the review, EMA's human medicines committee (CHMP) considered the results of clinical studies, data on side effects reported with these medicines, and advice from an expert group on infectious diseases.
Slovenian: Pri pregledu je Odbor za zdravila za uporabo v humani medicini (CHMP), ki deluje v okviru agencije EMA, upošteval rezultate kliničnih študij, podatke o neželenih učinkih, o katerih so poročali pri teh zdravilih, in nasvet strokovne skupine za nalezljive bolezni.
English: This followed a review that concluded that there are no robust data showing that these medicines are effective at treating existing respiratory infections, or for the prevention of pneumonia, therefore they should not be used for these purposes.
Slovenian: Ta sklep temelji na pregledu, v katerem je bilo ugotovljeno, da ni zanesljivih podatkov, ki bi pokazali, da so ta zdravila učinkovita pri zdravljenju obstoječih okužb dihal ali za preprečevanje pljučnice, zato se ne bi smela uporabljati za te namene.
English: On 27 June 2019, EMA recommended that bacterial lysate medicines authorised for respiratory conditions should only be used for the prevention of recurrent respiratory infections, with the exception of pneumonia.
Slovenian: Evropska agencija za zdravila je 27. junija 2019 priporočila, da se zdravila na osnovi bakterijskih lizatov lahko uporabljajo samo za preprečevanje ponavljajočih se okužb dihal, z izjemo pljučnice.
English: • Bacterial lysate medicines should not be used to treat existing infections of the airways or to prevent pneumonia (a lung infection) because there are not enough data to show that they work for these uses.
Slovenian: • Zdravila na osnovi bakterijskih lizatov se ne smejo uporabljati za zdravljenje obstoječih okužb dihalnih poti ali za preprečevanje pljučnice (okužbe pljuč), ker ne obstaja dovolj podatkov, ki bi dokazali njihovo učinkovitost pri takšni uporabi teh zdravil.
English: • The indications of bacterial lysate medicines have been restricted to prophylaxis of recurrent respiratory tract infections, with the exception of pneumonia.
Slovenian: • Indikacije za zdravila na osnovi bakterijskih lizatov so bile omejene na preprečevanje ponavljajočih se okužb dihal, z izjemo pljučnice.
English: • The prescribing information of the medicines is being updated with the new indication and a warning against use for prevention of pneumonia.
Slovenian: • V informacije o predpisovanju teh zdravil bo dodana nova indikacija in opozorilo, da se ta zdravila ne smejo uporabljati za preprečevanje pljučnice.
English: • Bacterial lysate medicines can continue to be used to prevent infections of the airways (except pneumonia) from coming back in patients who regularly get infections.
Slovenian: • Zdravila na osnovi bakterijskih lizatov se lahko še dalje uporabljajo za preprečevanje ponovitve okužb dihalnih poti (z izjemo pljučnice) pri bolnikih, ki pogosto obolevajo za temi boleznimi.
English: be prescribed for treatment of existing respiratory infections or for prophylaxis of pneumonia due to lack of efficacy data.
Slovenian: Zdravil na osnovi bakterijskih lizatov se ne sme predpisovati za zdravljenje obstoječih okužb dihal ali za preprečevanje pljučnice, saj za te indikacije ni na voljo dovolj podatkov o učinkovitosti.
English: Bacterial lysate medicines should not
Slovenian: Več o zdravilih na osnovi bakterijskih lizatov
English: 1 x 2 tablets (unit dose)
Slovenian: 1 x 2 tableti (enkratni odmerek)
English: Oral use blister (alu/PVC/PCT FE)
Slovenian: 90 mg filmsko obložena tableta peroralna uporaba pretisni omot (Al/PVC/PCTFE)
English: Further studies were carried out under laboratory conditions to confirm the other benefits of vaccination.
Slovenian: Nadaljnje študije so bile opravljene v laboratorijskih pogojih za potrditev drugih koristi cepljenja.
English: The vaccine helps to reduce the signs of these diseases.
Slovenian: Cepivo pripomore k zmanjšanju simptomov teh bolezni.
English: Further information on Leucofeligen FeLV/RCP can be found on the Agency's website: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
Slovenian: Nadaljnje informacije o zdravilu Leucofeligen FeLV/RCP so na voljo na spletni strani agencije: ema.europa.eu/Find medicine/Veterinary medicines/European public assessment reports.
English: One year after the initial vaccination a booster vaccination should be given.
Slovenian: Eno leto po začetnem cepljenju je treba dati obnovitveno injekcijo.
English: The FeLV protein used in the vaccine is not extracted from viruses but is made in a bacterium using ‘recombinant DNA technology'.
Slovenian: Beljakovina FeLV, uporabljena v cepivu, ni pridobljena iz virusov, pač pa je bila narejena v bakteriji s „tehnologijo rekombinantne DNK“.
English: The first injection is given when the kitten is about eight weeks old, and the second three or four weeks later.
Slovenian: Prvo injekcijo mladič prejme pri približno osmih tednih starosti, drugo pa tri do štiri tedne pozneje.
English: The contents of the two vials are mixed together before use to make up a suspension for injection.
Slovenian: Vsebini obeh vial se pred uporabo zmešata v raztopino za injiciranje.
English: The European Medicines Agency decided that Leucofeligen FeLV/RCP's benefits are greater than its risks and it can be authorised for use in the EU.
Slovenian: Evropska agencija za zdravila je odločila, da so koristi zdravila Leucofeligen FeLV/RCP večje od z njim povezanih tveganj in da se lahko odobri za uporabo v EU.
English: The most common side effects with Leucofeligen FeLV/RCP (which may affect up to 1 in 10 cats) are a moderate and short-lived local reaction (<2 cm) after the first injection which resolves without treatment within 3 to 4 weeks, raised body temperature (lasting 1 to 4 days), apathy (listlessness) and digestive disturbances.
Slovenian: Najpogostejši neželeni učinki zdravila Leucofeligen FeLV/RCP (ki lahko prizadenejo največ 1 mačko od 10) so zmerna in kratkotrajna lokalna reakcija (< 2 cm) po prvi injekciji, ki običajno izzveni v treh ali štirih tednih brez zdravljenja, povišana telesna temperatura (ki traja od enega do štirih dni), apatija (ravnodušnost) in prebavne motnje.
English: Because Leucofeligen FeLV/RCP is made up of two vaccines that have been available in the European Union (EU) since the 1980s (Feligen RCP and Leucogen), the company used data from studies carried out with these vaccines to support the use of Leucofeligen FeLV/RCP.
Slovenian: Ker je zdravilo Leucofeligen FeLV/RCP narejeno iz dveh cepiv, ki sta v Evropski uniji (EU) na voljo od osemdesetih let dvajsetega stoletja (Feligen RCP in Leucogen) je podjetje v podporo uporabi zdravila Leucofeligen FeLV/RCP uporabilo podatke iz študij, opravljenih s tema dvema cepivoma.
English: A laboratory study in which cats were exposed to feline leukaemia virus confirmed that following the first annual booster vaccination cats were protected for a three year period against leukaemia.
Slovenian: Laboratorijska študija, v kateri so bile mačke izpostavljene virusu mačje levkemije, je potrdila, da so te po prvem letnem obnovitvenem cepljenju pred levkemijo zaščitene tri leta.
English: It also contains a protein of feline leukaemia virus (FeLV).
Slovenian: Vsebuje tudi beljakovino virusa mačje levkemije (FeLV).
English: Leucofeligen FeLV/RCP contains small amounts of the three weakened viruses as listed above and a protein from the outer layer of FeLV called ‘envelope p45 protein'.
Slovenian: Zdravilo Leucofeligen FeLV/RCP vsebuje majhne količine treh vrst oslabljenih virusov, ki so našteti zgoraj, in beljakovino iz zunanje ovojnice FeLV, imenovano „beljakovina ovojnice p45“.
English: In addition, it reduced the excretion of feline viral rhinotracheitis viruses, prevented a fall in white blood cell counts in feline panleucopenia and prevented FeLV from remaining in the blood.
Slovenian: Poleg tega je zmanjšalo izločanje mačjih virusnih rinotraheitis virusov, preprečilo padec ravni belih krvnih celic pri panlevkopeniji mačk in preprečilo ostajanje FeLV v krvi.
English: The vaccine contains live feline viruses that have been attenuated (weakened) so they do not cause disease: feline calicivirus (strain F9), viral rhinotracheitis virus (strain F2) and feline panleucopenia virus (strain LR 72).
Slovenian: Virus vsebuje žive mačje viruse, ki so bili atenuirani (oslabljeni) in tako ne povzročajo bolezni: mačji kalicivirus (sev F9), virus virusnega rinotraheitisa (sev F2) in virus mačje panlevkopenije (sev LR 72).
English: For more information about using Leucofeligen FeLV/RCP, see the package leaflet or contact your veterinarian or pharmacist.
Slovenian: Za več informacij glede uporabe zdravila Leucofeligen FeLV/RCP glejte navodilo za uporabo ali se posvetujte z veterinarjem ali farmacevtom.
English: The studies showed that Leucofeligen FeLV/RCP provided protection against the diseases listed above as measured by the presence of antibodies against the viruses in the vaccinated kittens' blood.
Slovenian: Študije so pokazale, da je zdravilo Leucofeligen FeLV/RCP zagotovilo zaščito pred zgoraj naštetimi boleznimi, pri čemer je bilo merilo prisotnost protiteles proti virusom v krvi cepljenih mladičev.
English: Leucofeligen FeLV/RCP has been examined in two main ‘field' studies involving kittens aged eight to nine weeks.
Slovenian: Zdravilo Leucofeligen FeLV/RCP je bilo proučeno v dveh glavnih študijah na terenu z mačjimi mladiči, starimi od osem do devet tednov.
English: When a cat is given the vaccine, the immune system recognises the weakened viruses and the FeLV proteins as ‘foreign' and makes antibodies against them.
Slovenian: Ko mačko cepimo, imunski sistem prepozna oslabljene viruse in beljakovine virusa FeLV kot tujek ter proti njim razvije protitelesa.
English: The vaccine starts to protect against panleucopenia and leukaemia 3 weeks after the second injection and protection against calicivirosis and viral rhinotracheitis starts 4 weeks after the second injection.
Slovenian: Cepivo začne ščititi pred panlevkopenijo in levkemijo tri tedne po drugem injiciranju, pred kalicivirozo in virusnim rinotraheitisom pa štiri tedne po drugem injiciranju.
English: Leucofeligen FeLV/RCP is available as two vials, one containing a white powder pellet and one containing a liquid.
Slovenian: Zdravilo Leucofeligen FeLV/RCP je na voljo v obliki dveh vial, od katerih ena vsebuje bele pelete, druga pa tekočino.
English: Leucofeligen FeLV/RCP is a vaccine.
Slovenian: Zdravilo Leucofeligen FeLV/RCP je cepivo.
English: Leucofeligen FeLV/RCP should not be used in pregnant cats.
Slovenian: Zdravilo Leucofeligen FeLV/RCP se ne sme uporabljati pri brejih mačkah.
English: Other information about Leucofeligen FeLV/RCP
Slovenian: Druge informacije o zdravilu Leucofeligen FeLV/RCP
English: For the full list of side effects and restrictions with Leucofeligen FeLV/RCP, see the package leaflet.
Slovenian: Za celoten seznam neželenih učinkov in omejitev zdravila Leucofeligen FeLV/RCP glejte navodilo za uporabo.
English: An overview of Leucofeligen FeLV/RCP and why it is authorised in the EU
Slovenian: Pregled zdravila Leucofeligen FeLV/RCP in zakaj je odobreno v EU
English: Why is Leucofeligen FeLV/RCP authorised in the EU?
Slovenian: Zakaj je bilo zdravilo Leucofeligen FeLV/RCP odobreno v EU?
English: It also prevents feline panleucopenia and persistent viraemia for feline leukaemia (the presence of feline leukaemia virus in the blood).
Slovenian: Preprečuje tudi panlevkopenijo mačk in trajno viremijo pri levkemiji mačk (prisotnost virusa levkemije mačk v krvi).
English: What is Leucofeligen FeLV/RCP and what is it used for?
Slovenian: Kaj je zdravilo Leucofeligen FeLV/RCP in za kaj se uporablja?
English: In the future, the cat's immune system will be able to produce antibodies more quickly when it is exposed to the disease-causing forms of the viruses.
Slovenian: Ob ponovni izpostavitvi oblikam virusov, ki povzročajo bolezni, bo lahko imunski sistem mačke hitreje tvoril protitelesa.
English: FeLV/RCP only every 3 years, with annual revaccination in intervening years with the vaccine Feligen RCP to protect against calicivirosis, rhinotracheitis and panleucopenia.
Slovenian: Zato starejše mačke potrebujejo ponovno cepljenje z zdravilom Leucofeligen FeLV/RCP samo vsaka tri leta ter ponovno cepljenje z zdravilom Feligen RCP vsako leto v vmesnih letih za zaščito pred kalicivirozo, rinotraheitisom in panlevkopenijo.
English: The vaccine also contains aluminium hydroxide and extract of Quillaja saponaria as adjuvants (ingredients that strengthen the immune response).
Slovenian: Cepivo kot dodatka (sestavini, ki spodbudita imunski odziv) vsebuje tudi aluminijev hidroksid in izvleček Quillaja saponaria.
English: Leucofeligen FeLV/RCP is given to kittens as two injections under the skin.
Slovenian: Zdravilo Leucofeligen FeLV/RCP se mačjim mladičem injicira pod kožo v dveh odmerkih.
English: What benefits of Leucofeligen FeLV/RCP have been shown in studies?
Slovenian: Kakšne koristi je zdravilo Leucofeligen FeLV/RCP izkazalo v študijah?
English: Protection against leukaemia lasts for 3 years once a booster has been given and lasts for one year for calicivirosis and viral rhinotracheitis.
Slovenian: Zaščita pred levkemijo traja tri leta po obnovitvenem odmerku, zaščita pred kalicivirozo in virusnim rinotraheitisom pa traja eno leto.
English: What are the risks associated with Leucofeligen FeLV/RCP?
Slovenian: Kakšna tveganja so povezana z zdravilom Leucofeligen FeLV/RCP?
English: Its use is not recommended in cats nursing kittens.
Slovenian: Prav tako njegova uporaba ni priporočljiva v obdobju laktacije.
English: Leucofeligen FeLV/RCP received a marketing authorisation valid throughout the EU on <date of issue of the Marketing Authorisation>.
Slovenian: Zdravilo Leucofeligen FeLV/RCP je pridobilo dovoljenje za promet, veljavno po vsej Evropski uniji, 25. junija 2009.
English: How is Leucofeligen FeLV/RCP used?
Slovenian: Kako se zdravilo Leucofeligen FeLV/RCP uporablja?
English: How does Leucofeligen FeLV/RCP work?
Slovenian: Kako zdravilo Leucofeligen FeLV/RCP deluje?
English: Leucofeligen FeLV/RCP is a vaccine used to protect cats from eight weeks of age against the following diseases: feline calicivirosis (a flu-like illness with inflammation of the mouth caused by a calicivirus); feline viral rhinotracheitis (a flu-like illness caused by a herpesvirus); feline panleucopenia (a serious illness causing bloody diarrhoea and a fall in white blood cell counts caused by a parvovirus); feline leukaemia (an illness affecting the immune system causing loss of appetite, weight loss, poor fur condition, fever, pale gums and diarrhoea caused by a retrovirus).
Slovenian: levkemiji mačk (bolezni, ki prizadene imunski sistem in povzroča izgubo teka, hujšanje, slabo stanje dlake, povišano telesno temperaturo, blede dlesni in drisko ter jo povzroča retrovirus).
English: Annex I List of the names, pharmaceutical form, strengths of the medicinal products, route of administration, marketing authorisation holders in the Member States
Slovenian: Priloga I Seznam imen, farmacevtskih oblik, jakosti zdravila, poti uporabe zdravila, imetnikovdovoljenja za promet z zdravilom v državah članicah
English: Sandoz Limited Frimley Business Park Frimley, Camberley Surrey GU16 7SR United Kingdom
Slovenian: Velika Britanija Sandoz Limited Frimley Business Park Frimley, Camberley Surrey GU16 7SR United Kingdom
English: Perryment Ltd 42-46 High street Esher, KT10 9QY Surrey United Kingdom
Slovenian: Nizozemska Perryment Ltd 42-46 High street Esher, KT10 9QY Surrey United Kingdom
English: Levonorgestrel-containing emergency contraceptive medicinal products Member State (in EEA)
Slovenian: Za zdravila, ki vsebujejo levonorgestrel in se uporabljajo za nujno kontracepcijo Država članica (v
English: Gedeon Richter Romania S.A. Str. Cuza-Vodă nr. 99-105 Târgu Mureş 540306
Slovenian: Str. Cuza-Vodă nr. 99-105 Târgu Mureş 540306
English: Belgium Sandoz N.V. Telecom Gardens Medialaan 40
Slovenian: Telecom Gardens Medialaan 40
English: Czech Republic Gedeon Richter Plc.
Slovenian: Velika Britanija Gedeon Richter Plc.
English: Luxembourg Laboratoire HRA Pharma 15, rue Béranger
Slovenian: Luksemburg Laboratoire HRA Pharma 15, rue Béranger
English: Belgium Laboratoire HRA Pharma 15, rue Béranger
Slovenian: Portugalska Laboratoire HRA Pharma 15, rue Béranger
English: Laboratorios Leon Farma SA Calle La Vallina S/N Poligono Industrial Navatejera Navatejera, Leon E-24008 Spain
Slovenian: Laboratorios León Farma S.A. Calle La Vallina s/n Polígono Industrial Navatejera 24008 - Navatejera - León Spain
English: Luxembourg Medimpex UK Limited 127 Shirland Road
Slovenian: Luksemburg Medimpex UK Limited 127 Shirland Road
English: Belgium Medimpex UK Limited 127 Shirland Road
Slovenian: Velika Britanija Medimpex UK Limited 127 Shirland Road
English: Polígono Industrial Navatejera 24008 - Navatejera - León Spain
Slovenian: Poligono Industrial Navatejera Navatejera, Leon E-24008
English: Czech Republic Laboratorios León Farma S.A. Calle La Vallina s/n
Slovenian: Velika Britanija Laboratorios Leon Farma SA Calle La Vallina S/N
English: Supportive data suggested that the benefit was maintained for up to two years.
Slovenian: Podporni podatki so nakazali, da so se koristi ohranile do dve leti.
English: The recommended dose is 3 mg for each kg of bodyweight.
Slovenian: Priporočeni odmerek je 3 mg na vsak kilogram telesne mase.